Interaction Guide · Research summary

Can I take Piper Methysticum with Orphenadrine?

Review Piper Methysticum with Orphenadrine: possible adverse effects, preparation details, evidence limits, and sources.

Prepared by Dr. Edward M.Kim, PharmD · Clinical Director, SupplementSafety editorial team

Research summary published · Prepared · Editorial update

The short answer

Kava may add to orphenadrine-related drowsiness or impaired alertness. Review the exact product and other sedating medicines before adding it; this combination’s risk has not been measured directly.

What this answer covers

Piper methysticum preparations; extract, beverage and dose vary.

Supplement or preparation
Piper methysticum
Medication ingredient
orphenadrine

The medicine can affect alertness

Anticholinergic effects, dizziness, drowsiness and impaired driving; tachycardia and urinary retention precautions. These medication warnings do not supply a supplement-specific adverse-event rate.

What the supplement evidence shows

A small driving-simulator crossover found no significant impairment after one medicinal kava dose. Kava and oxazepam were taken in separate sessions. That null result does not establish safety of simultaneous co-use or stronger extracts.

Keep the preparation and outcome clear

Dose, formulation and other ingredients matter. No exact-pair trial identified here established how much impairment would increase, and a negative result for one product alone does not prove the combination safe.

Review co-use and daily activities

Discuss the product with the prescriber or pharmacist before adding it. Avoid driving while drowsy or dizzy. No exact protective spacing interval was established, and a supplement should not be used to counteract medication impairment.

Evidence and practical considerations

Side effects & toxicity

Conditional additive-alertness precaution from medication-specific effects and supplement guidance; direct pair harm, respiratory depression rate and protective spacing not established.

Exact scope
Piper methysticum preparations; extract, beverage and dose vary. with Oral orphenadrine citrate extended-release tablets; fixed aspirin/caffeine combination distinguished.
Medication form and route
oral medication; oral supplement

What remains uncertain

  • No unmeasured pair incidence, blanket class transfer or arbitrary spacing interval.

Factors that may matter: Preparation; Dose; Other medicines; Organ function.

Research conclusion: supported with conditions · Evidence assessment: low

Read the supporting source summaries

Source 1: current product label

dailymed.nlm.nih.gov · Source check Sep 10, 2026

Population: People prescribed orphenadrine

Anticholinergic effects, dizziness, drowsiness and impaired driving; tachycardia and urinary retention precautions.

How this applies: Exact orphenadrine RxCUI 7715 IN, with stated salt/formulation/route bridge.

No exact supplement-combination incidence or validated protective spacing; salt, route and release form limits apply.

Source 2: Federal supplement guidance

nccih.nih.gov · Source check Sep 10, 2026

Population: People considering the named botanical or supplement.

Advises against combining kava with other sedating substances. Products vary and separate liver-injury concerns are described.

How this applies: Interpreted for orphenadrine only within the stated exact preparation and endpoint limits.

No exact orphenadrine combination trial; original population, preparation and endpoint restrictions apply. No quantified pair risk or protective dose interval.

Source 3: Original human study

pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026

Population: Twenty-two adults in a crossover driving-simulator trial.

Kava did not significantly impair driving compared with placebo; oxazepam impaired selected measures.

How this applies: Interpreted for orphenadrine only within the stated exact preparation and endpoint limits.

No exact orphenadrine combination trial; original population, preparation and endpoint restrictions apply. No quantified pair risk or protective dose interval.

Research assessment: · Open full citations ↗

Review and change history

Publication status
Published research summary
Clinical review
Not yet recorded
DateUpdate
Research summary published
Article prepared
Prepared exact orphenadrine article with formulation-specific evidence and uncertainty.

Article revision: f4ae79ba1ea997ee

This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.

Full citations require verification. Reading this answer and the source summaries does not.

Taking other supplements or medications?

Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.

Open the interaction checker

Information, not medical advice. Do not change prescribed treatment based on this guide.